$ALLO News
Last published 2d ago
- 2d agoALLOAllogene Therapeutics Conference Call - ALLOGENE THERAPEUTICS INCEarnings Call TranscriptsHello, thank you for standing by and welcome to Allogene Therapeutics conference call. After the speaker's presentation, there will be a question and answer session. At this time, all participants are in a listen-only mo
- 2d agoALLOAllogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune DiseaseGlobeNewswireFavorable Early Safety Profile in 18 Patients with No DLTs, IEC-HS, ICANS, GvHD or Grade ≥3 CRSInitial Efficacy Analysis Focused on Skin-Predominant...
- 2d agoALLOAllogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune DiseaseGlobeNewswireFavorable Early Safety Profile in 18 Patients with No DLTs, IEC-HS, ICANS, GvHD or Grade ≥3 CRSInitial Efficacy Analysis Focused on Skin-Predominant Systemic Sclerosis (SSc/Scleroderma), a Severe Autoimmune Disease with
- 6d agoALLOAllogene Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoALLOAllogene Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdateGlobeNewswirePivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Brisk Enrollment in Asia-PacificNext ALPHA3
- 1w agoALLOAllogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual MeetingGlobeNewswireTwo Invited Presentations Showcase Clinical Progress in Solid Tumors and Allogene's Broader Vision in Oncology and Autoimmune DiseasePreclinical Poster Features Next-Generation DLL3/CD70 Dual CAR T Product Candidate
- 1w agoALLOAllogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical DataGlobeNewswireQ3 2026 Financial Results and Business Update Conference Call and Webcast Scheduled for November 5, 2026 at 2:00 p.m. PT/5:00 p.m. ETALLO-329 Autoimmune Disease Program Webinar Featuring Preliminary Safety and Efficacy
- 2w agoALLOAllogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for
- 2mo agoALLOAllogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey ParkerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for
- 2mo agoALLOAllogene Therapeutics Announces Participation in September Investor ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for
- 3mo agoALLOThe Allogene Therapeutics Second Quarter 2026 Conference Call - ALLOGENE THERAPEUTICS INCEarnings Call TranscriptsHello. Thank you for standing by, and welcome to Allogene Therapeutics' second quarter 2026 conference call. After the speaker's presentation, there will be a question and answer session. To ask a question during the ses
- 3mo agoALLOAllogene Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdateGlobeNewswirePivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation
- 3mo agoALLOAllogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business UpdateGlobeNewswireConference Call and Webcast Scheduled for August 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage
- 3mo agoALLOAllogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell LymphomaGlobeNewswireFDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel’s Potential to Transform Disease Treatment in First-Line LBCL Consolidation Cema-Cel Induced Rapid and Substantial MRD
- 3mo agoALLOAllogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid TumorsGlobeNewswireALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in
- 5mo agoALLOAllogene Therapeutics Announces Planned CEO SuccessionGlobeNewswireDavid Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of DirectorsZachary Roberts, M.D., Ph.D., EVP,
- 5mo agoALLOAllogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for
- 6mo agoALLOAllogene Therapeutics Reports First Quarter 2026 Financial Results and Business UpdateGlobeNewswirePlanned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel's (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL) 58.3%
- 6mo agoALLOAllogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateGlobeNewswireConference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology
- 6mo agoALLOAllogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and AustraliaGlobeNewswireExpansion Adds to Growing Global Trial FootprintPatient Screening and Enrollment Expected to Begin in Q2 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO),
- 6mo agoALLOAllogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products,
- 6mo agoALLOAllogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000 shares of its
- 7mo agoALLOAllogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune DiseasesGlobeNewswireStudy Highlights Dagger® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-Clinical
- 7mo agoALLOAllogene Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a
- 7mo agoALLOAllogene Therapeutics Announces Proposed Public Offering of $175 Million of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and
- 7mo agoALLONTRANatera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell LymphomaBusiness WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ:ALLO) interim futility analysis from its registrational ALPHA3 trial for
- 7mo agoALLOAllogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCLGlobeNewswire41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment with a 97.7% Median
- 7mo agoALLOAllogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for
- 8mo agoALLOAllogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdateGlobeNewswirePivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation
- 8mo agoALLOAllogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business UpdateGlobeNewswireConference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage
- 9mo agoALLOAllogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for
- 10mo agoALLOCHRSELVNONCY+1The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent CliffGlobeNewswireVANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming
- 10mo agoALLOAllogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR TGlobeNewswire1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene
- 11mo agoALLOCLLSAllogene Therapeutics Reports Favorable Result for Servier in Arbitration with CellectisGlobeNewswireArbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the
- 1y agoALLOAllogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)
- 1y agoALLOAllogene Therapeutics Reports Third Quarter 2025 Financial Results and Business UpdateGlobeNewswirePivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology
- 1y agoALLOAllogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)
- 1y agoALLOAllogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business UpdateGlobeNewswireConference Call and Webcast Scheduled for November 6, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage
- 1y agoALLOAllogene Therapeutics Announces Participation in Upcoming Investor ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)
- 1y agoALLOAllogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoALLOAllogene Therapeutics Reports Second Quarter 2025 Financial Results and Business UpdateGlobeNewswirePivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After
- 1y agoALLOAllogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business UpdateGlobeNewswireConference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage
- 1y agoALLOAllogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell LymphomaGlobeNewswireLymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC
- 1y agoONCYCUEVSTMALLO+1High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy HeadwindsPR NewswireUSA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets ...
- 1y agoALLOAllogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCOGlobeNewswireData Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A
- 1y agoALLOAllogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)
- 1y agoALLOAllogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-CelGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)
- 1y agoALLOAllogene Therapeutics Reports First Quarter 2025 Financial Results and Business UpdateGlobeNewswirePivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from
- 1y agoALLOAllogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business UpdateGlobeNewswireConference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage
- 1y agoALLOAllogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)